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We thank Pang et al. for their interest in our recently published
systematic review and meta-analysis involving 2605 patients
which found no association between baseline 25-hydroxyvitamin
D level and sustained virologic response (SVR) to interferon-
based antiviral therapy in chronic hepatitis C infection [1]. They
are correct to highlight the inﬂuence of ethnicity on both vitamin
D status and genetic polymorphisms in key proteins involved in
vitamin D synthesis. The studies included in our meta-analysis
contained only a small number of participants of Asian [2] or
African-American [3] ethnicity, leading us to highlight the study’s
inability to adjust for ethnicity as one of its limitations.
With regards to the recently published meta-analysis by
García-Álvarez et al. [4] evaluating vitamin D status and response
to hepatitis C therapy, this study differs from ours in that it
includes those with HCV-HIV co-infection. Furthermore, we
believe this study has signiﬁcant methodological issues such as
the inclusion of three studies involving the same Italian cohort
of approximately 200 patients, and the exclusion of ﬁve large
studies [2,5–8] from Europe and Australia involving 1569
patients that were readily identiﬁable using the stated search
strategy. Our concerns about this study have recently been pub-
lished [9] and the validity of the study’s ﬁndings should be
viewed with caution.
Our meta-analysis only evaluates the relationship between
baseline vitamin D status and SVR. The impact of vitamin D sup-
plementation on outcomes to interferon-based antiviral therapy,
although interesting, is a different clinical question that has notJournal of Hepatology 20
ccess under CC BY-NC-ND license.been deﬁnitively assessed in prospective, randomized controlled
trials. We agree that vitamin D has potential anti-viral, anti-
inﬂammatory, anti-ﬁbrotic and immunomodulatory actions rele-
vant to liver disease, which have been highlighted in a number
of pre-clinical studies [10]. However high quality prospective
clinical research studies are needed to support the hypothesis
that vitamin D deﬁciency may be responsible for the worse
outcomes in HCV related liver disease.
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Hepatocyte senescence explains conjugated bilirubinaemia
in chronic liver failure
To the Editor:
Conjugated bilirubinaemia in patients with chronic liver disease
(CLD) reﬂects hepatic decompensation and a poor prognosis [1].
The pathophysiology that underlies conjugated bilirubinaemia
in hepatic decompensation is poorly understood. There is no
demonstrable ﬂaw in processing unconjugated bilirubin and a
more likely explanation is altered hepatocyte handling of conju-
gated bilirubin.
Hepatocyte senescence is present across diverse aetiologies
and as many as 80% of hepatocytes show the senescent pheno-
type in advanced liver disease [2]. Metabolic activity is altered
when a cell becomes senescent and one potential consequence
is an alteration of conjugated bilirubin transport in senescent
hepatocytes, which accumulate in advanced CLD.
Serum bilirubin and hepatocyte telomere length were
measured in 70 patients within the spectrum of NAFLD. Mean
hepatocyte telomere intensity, a surrogate marker of telomere
length, was measured using quantitative ﬂuorescent in-situ
hybridization, as described [3]. There was an inverse relationship
between serum bilirubin and hepatocyte telomere length
(p = 0.04, Fig. 1). Thus, accelerated hepatocyte ageing is associ-
ated with jaundice.
Liver sections from ﬁve of those patients were double-stained
using unconjugated mouse monoclonal anti-p21 (Dako; concen-
tration 1:100, heat-induced EDTA-based antigen retrieval,
20 min) and unconjugated mouse monoclonal anti-MRP2
(Merck Millipore; concentration 1:20, heat-induced citrate-
based antigen retrieval, 20 min). MRP2 was negative in p21-
positive (senescent) hepatocytes and was only detected in
p21-negative hepatocytes (Fig. 1). Reliable immunohistochemi-
cal staining could not be achieved with available MRP3
antibodies.
An in vitro model was used to examine gene expression of
MRP2 and MRP3 in senescent hepatocytes by real-time PCR.
Cellular senescence was induced in HepG2 cells by incubation
with 0.5 mMH2O2 in culturemedium for 60 minutes, as described
[4]. Expression of MRP2 was downregulated in senescent
HepG2 cells; in contrast, expression of MRP3 was upregulated
(Fig. 1).
Hepatocytes are polarised cells; MRP2 is restricted to the
canalicular (apical) membrane, whereas MRP3 is found only in
the sinusoidal (basolateral) membrane [5]. Both MRP2 and
MRP3 are unidirectional efﬂux pumps, which transport
conjugated bilirubin into the canalicular space (bile) or the
sinusoid (blood), respectively [5]. Reduced MRP2 expression in
senescent hepatocytes in vitro and an absence of MRP2 protein
in p21-positive (senescent) hepatocytes suggest reduced conju-
gated bilirubin transport into the biliary canaliculi. Increased
MRP3 expression in senescent hepatocytes may be compen-
satory, increasing transport of conjugated bilirubin into the hep-
atic sinusoid (Fig. 1). It is, however, not clear why changes in
MRP2 and MRP3 accompany hepatocyte senescence.
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